trending Market Intelligence /marketintelligence/en/news-insights/trending/pyhl6862skmsbsovpq2bxa2 content esgSubNav
In This List

Gilead Sciences licenses California-based company's drug discovery technology

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Gilead Sciences licenses California-based company's drug discovery technology

Gilead Sciences Inc. said it entered a license agreement with San Francisco-based Trianni Inc. to use its drug discovery platform.

The financial details of the agreement were not disclosed in a Sept. 4 news release.

Trianni's transgenic human monoclonal antibody discovery platform uses genetically engineered mice to generate antibodies that can be effective in humans.